Natural antioxidants in Alzheimer's disease

Cesare Mancuso, Timothy E. Bates, D. Allan Butterfield, Stella Calafato, Carolin Cornelius, Antonino De Lorenzo, Albena T. Dinkova Kostova, Vittorio Calabrese

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists to the NMDA receptors. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. In the past several years, based on in vitro and in vivo studies in laboratory animals, natural antioxidants, such as resveratrol, curcumin and acetyl-L-carnitine have been proposed as alternative therapeutic agents for AD. An increasing number of studies demonstrated the efficacy of primary antioxidants, such as polyphenols, or secondary antioxidants, such as acetylcarnitine, to reduce or to block neuronal death occurring in the pathophysiology of this disorder. These studies revealed that other mechanisms than the antioxidant activities could be involved in the neuroprotective effect of these compounds. This paper discusses the evidence for the role of acetylcarnitine in modulating redox-dependent mechanisms leading to the upregulation of vitagenes. Furthermore, future development of novel antioxidant drugs targeted to the mitochondria should result in effectively slowing disease progression. The association with new drug delivery systems may be desirable and useful for the therapeutic use of antioxidants in human neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)1921-1931
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Alzheimer Disease
Antioxidants
Acetylcarnitine
Neurodegenerative Diseases
Pharmaceutical Preparations
Curcumin
Cholinesterase Inhibitors
Laboratory Animals
Polyphenols
Neuroprotective Agents
Therapeutic Uses
Drug Delivery Systems
N-Methyl-D-Aspartate Receptors
Cognition
Oxidation-Reduction
Disease Progression
Mitochondria
Up-Regulation
Therapeutics

Keywords

  • Acetyl-L-carnitine
  • Alzheimer's disease
  • Curcumin
  • Haem oxygenase
  • Heat-shock proteins
  • Resveratrol
  • Vitagenes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mancuso, C., Bates, T. E., Butterfield, D. A., Calafato, S., Cornelius, C., De Lorenzo, A., ... Calabrese, V. (2007). Natural antioxidants in Alzheimer's disease. Expert Opinion on Investigational Drugs, 16(12), 1921-1931. https://doi.org/10.1517/13543784.16.12.1921

Natural antioxidants in Alzheimer's disease. / Mancuso, Cesare; Bates, Timothy E.; Butterfield, D. Allan; Calafato, Stella; Cornelius, Carolin; De Lorenzo, Antonino; Dinkova Kostova, Albena T.; Calabrese, Vittorio.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 12, 12.2007, p. 1921-1931.

Research output: Contribution to journalArticle

Mancuso, C, Bates, TE, Butterfield, DA, Calafato, S, Cornelius, C, De Lorenzo, A, Dinkova Kostova, AT & Calabrese, V 2007, 'Natural antioxidants in Alzheimer's disease', Expert Opinion on Investigational Drugs, vol. 16, no. 12, pp. 1921-1931. https://doi.org/10.1517/13543784.16.12.1921
Mancuso C, Bates TE, Butterfield DA, Calafato S, Cornelius C, De Lorenzo A et al. Natural antioxidants in Alzheimer's disease. Expert Opinion on Investigational Drugs. 2007 Dec;16(12):1921-1931. https://doi.org/10.1517/13543784.16.12.1921
Mancuso, Cesare ; Bates, Timothy E. ; Butterfield, D. Allan ; Calafato, Stella ; Cornelius, Carolin ; De Lorenzo, Antonino ; Dinkova Kostova, Albena T. ; Calabrese, Vittorio. / Natural antioxidants in Alzheimer's disease. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 12. pp. 1921-1931.
@article{3c28e3b340bd4741b67b2535e52e1e73,
title = "Natural antioxidants in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists to the NMDA receptors. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. In the past several years, based on in vitro and in vivo studies in laboratory animals, natural antioxidants, such as resveratrol, curcumin and acetyl-L-carnitine have been proposed as alternative therapeutic agents for AD. An increasing number of studies demonstrated the efficacy of primary antioxidants, such as polyphenols, or secondary antioxidants, such as acetylcarnitine, to reduce or to block neuronal death occurring in the pathophysiology of this disorder. These studies revealed that other mechanisms than the antioxidant activities could be involved in the neuroprotective effect of these compounds. This paper discusses the evidence for the role of acetylcarnitine in modulating redox-dependent mechanisms leading to the upregulation of vitagenes. Furthermore, future development of novel antioxidant drugs targeted to the mitochondria should result in effectively slowing disease progression. The association with new drug delivery systems may be desirable and useful for the therapeutic use of antioxidants in human neurodegenerative diseases.",
keywords = "Acetyl-L-carnitine, Alzheimer's disease, Curcumin, Haem oxygenase, Heat-shock proteins, Resveratrol, Vitagenes",
author = "Cesare Mancuso and Bates, {Timothy E.} and Butterfield, {D. Allan} and Stella Calafato and Carolin Cornelius and {De Lorenzo}, Antonino and {Dinkova Kostova}, {Albena T.} and Vittorio Calabrese",
year = "2007",
month = "12",
doi = "10.1517/13543784.16.12.1921",
language = "English (US)",
volume = "16",
pages = "1921--1931",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Natural antioxidants in Alzheimer's disease

AU - Mancuso, Cesare

AU - Bates, Timothy E.

AU - Butterfield, D. Allan

AU - Calafato, Stella

AU - Cornelius, Carolin

AU - De Lorenzo, Antonino

AU - Dinkova Kostova, Albena T.

AU - Calabrese, Vittorio

PY - 2007/12

Y1 - 2007/12

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists to the NMDA receptors. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. In the past several years, based on in vitro and in vivo studies in laboratory animals, natural antioxidants, such as resveratrol, curcumin and acetyl-L-carnitine have been proposed as alternative therapeutic agents for AD. An increasing number of studies demonstrated the efficacy of primary antioxidants, such as polyphenols, or secondary antioxidants, such as acetylcarnitine, to reduce or to block neuronal death occurring in the pathophysiology of this disorder. These studies revealed that other mechanisms than the antioxidant activities could be involved in the neuroprotective effect of these compounds. This paper discusses the evidence for the role of acetylcarnitine in modulating redox-dependent mechanisms leading to the upregulation of vitagenes. Furthermore, future development of novel antioxidant drugs targeted to the mitochondria should result in effectively slowing disease progression. The association with new drug delivery systems may be desirable and useful for the therapeutic use of antioxidants in human neurodegenerative diseases.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists to the NMDA receptors. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. In the past several years, based on in vitro and in vivo studies in laboratory animals, natural antioxidants, such as resveratrol, curcumin and acetyl-L-carnitine have been proposed as alternative therapeutic agents for AD. An increasing number of studies demonstrated the efficacy of primary antioxidants, such as polyphenols, or secondary antioxidants, such as acetylcarnitine, to reduce or to block neuronal death occurring in the pathophysiology of this disorder. These studies revealed that other mechanisms than the antioxidant activities could be involved in the neuroprotective effect of these compounds. This paper discusses the evidence for the role of acetylcarnitine in modulating redox-dependent mechanisms leading to the upregulation of vitagenes. Furthermore, future development of novel antioxidant drugs targeted to the mitochondria should result in effectively slowing disease progression. The association with new drug delivery systems may be desirable and useful for the therapeutic use of antioxidants in human neurodegenerative diseases.

KW - Acetyl-L-carnitine

KW - Alzheimer's disease

KW - Curcumin

KW - Haem oxygenase

KW - Heat-shock proteins

KW - Resveratrol

KW - Vitagenes

UR - http://www.scopus.com/inward/record.url?scp=39549119848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549119848&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.12.1921

DO - 10.1517/13543784.16.12.1921

M3 - Article

VL - 16

SP - 1921

EP - 1931

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -